Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647011 | 0.89 | CA1 (0.63) | RAB9AALDH1A1NPC1MAPTL3MBTL1 | |
| SCHEMBL2654385 | 0.89 | CA1 (0.63) | RAB9AALDH1A1NPC1MAPTL3MBTL1 | |
| SCHEMBL1789154 | 0.86 | ALDH1A1 (0.63) | RAB9AALDH1A1NPC1MAPTALOX15 | |
| SCHEMBL15534528 | 0.85 | HSP90AA1 (0.54) | RAB9AALDH1A1NPC1MAPTL3MBTL1 | |
| SCHEMBL2651897 | 0.83 | MEN1 (0.52) | RAB9AALDH1A1NPC1MAPTL3MBTL1 | |
| SCHEMBL2647028 | 0.82 | HAO1 (0.52) | ALDH1A1L3MBTL1MEN1KMT2AHSD17B10 | |
| SCHEMBL2654897 | 0.82 | CA1 (0.54) | RAB9AALDH1A1NPC1MAPTMEN1 | |
| SCHEMBL6427116 | 0.81 | MAPT (0.47) | RAB9AALDH1A1NPC1MAPTL3MBTL1 | |
| SCHEMBL5585283 | 0.81 | MAPT (0.51) | RAB9AALDH1A1NPC1MAPTL3MBTL1 | |
| SCHEMBL4051167 | 0.81 | MAPT (0.75) | RAB9AALDH1A1NPC1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-12-19 | — | — | US | disclosed |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-13 | — | — | US | disclosed |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-13 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | RAB9A 3373/4885ALDH1A1 722/4885NPC1 3700/4885 |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | RAB9A 3373/4885ALDH1A1 722/4885NPC1 3700/4885 |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | STAT3, STAT5A, STAT6 | RAB9A 3373/4885ALDH1A1 722/4885NPC1 3700/4885 |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, JAK2 | RAB9A 2792/4885ALDH1A1 836/4885NPC1 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.